READ FIRST – NeVa Training One Pager
START HERE – Watch the recorded sessions and other training resources by clicking on the links in the document.
READ FIRST – NeVa VS Training One Pager
START HERE – Watch the recorded sessions and other training resources by clicking on the links in the document.
NeVa VS Training Presentation
Loading… Taking too long? Reload document | Open in new tab Download [2.65 MB]
NeVa Product Family Roll Up Banners
Product brochure to be used as leave behind piece as needed.
Procedure Poster
Pocket guide to be shared with newly initiated sites and/or existing customers as a leave behind piece. Contact Market Development for help in organizing a pVasc Induction Webinar with your customer if needed.
EVT Article
Loading… Taking too long? Reload document | Open in new tab Download [6.16 MB]
Vesalio Announces Late-Breaking Clinical Trial Presentation of the enVast NATURE Study at the ESC Congress 2026
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology Congress.
Vesalio Appoints Greg Cook as Chief Commercial Officer
Greg Cook joins Vesalio as Chief Commercial Officer to lead commercial strategy and execution across its thrombectomy platform.
Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters.
Vesalio Receives FDA 510(k) Clearance of enVast, the First Stent-Based Coronary Thrombectomy Technology
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
